T he use of heparin for treatment of progressive ischemic stroke has been a widespread practice for the past 30 years. 1 In the late 1950s and early 1960s several controlled studies concluded that the 6-12 month outcome of patients with progressive stroke was improved by anticoagulation.
-
7 A well-designed randomized controlled clinical trial to evaluate heparin's effectiveness for the treatment of progressive stroke, however, has yet to be completed. Furthermore, reports on the acute outcome of patients with progressive stroke with or without heparin treatment are scarce. 5 -6 -8 The purpose of our study was to define the acute course in patients treated with heparin for progressive stroke. The Cornell Neurology Database provided this opportunity since the registry included all patients with progressive ischemic stroke treated with heparin between October 1979 and June 1985. Data analysis also permitted a determination of possible clinical features and heparin dosing regimens distinguishing a subgroup(s) of patients most likely to benefit from heparin. Such information will aid in the design of future therapeutic trials for progressive stroke.
Subjects and Methods
At the New York Hospital, data on hospitalized patients with ischemic stroke are entered into the Cornell Neurology Database. All patients with ischemic stroke who were treated with heparin from October 1979 to June 1985 were accessed from the Database. Hospital charts of these patients were then obtained, and those with progressive stroke were selected. Progressive stroke was defined as a focal ischemic neurologic deficit that by history worsened or fluctuated before hospital admission or that deteriorated on serial examinations after hospitalization. Patients with a new deficit in a different arterial distribution suggesting a separate ischemic insult were excluded, as were patients with a completed deficit, since further progression in these patients would be impossible to detect.
Information obtained from the hospital charts of progressive stroke patients included 1) age and sex, 2) arterial distribution of the stroke (left carotid, right carotid, vertebral-basilar), 3) day(s) from the onset of symptoms to the start of heparin treatment, 4) presence of a cardiac source of emboli (paroxys-mal or chronic atrial fibrillation, rheumatic heart disease, aortic or mitral valve stenosis or prosthesis, cardiomyopathy, or myocardial infarction during preceding 6 weeks), 5) treatment with antiplatelet agents prior to hospital admission, 6) number of days on heparin treatment, 7) number of days, if any, of concurrent heparin and antiplatelet therapy, 8) any invasive procedures performed just before or during heparin treatment, 9) type of antithrombotic medication received after heparin was discontinued, and 10) dates and results of cranial computed tomography (CT), carotid ultrasound, and cerebral angiography. CT results were used to classify stroke location as either cortical or subcortical based on the initial or a repeat scan. Patients with normal initial and follow-up scans were classified as having a subcortical stroke. Patients with only one CT scan done <24 hours after stroke onset were classified as having a stroke of indeterminate location if the scan was normal.
The clinical course while on heparin was determined for each patient on the basis of results of the daily neurologic examination recorded in the progress notes. Patients who developed at least one progressive neurologic deficit or a new deficit in the same arterial distribution as the presenting deficit were classified as worsened; all others were classified as stable. The cause of in-hospital deaths and the site of bleeding complications were determined from information available in the progress notes.
Heparin therapy was administered by continuous intravenous infusion, with or without an initial bolus. Medication sheets and nurses' notes were examined to obtain heparin dosing regimens. An average daily dose of heparin, including bolus injections, was calculated for each patient. Patients with neurologic deterioration or hemorrhage while on heparin had an average daily dose of heparin calculated for the day(s) they worsened or bled.
All the partial thromboplastin times (PTTs) obtained during heparin treatment were recorded, and a mean PTT was calculated for each patient, with PTT values of > 150 seconds counted as 155 seconds. Each PTT value was divided by the patient's preheparin PTT to obtain a PTT ratio. A mean PTT ratio for the entire treatment course was then calculated for each patient. Patients who worsened or hemorrhaged while on heparin also had a mean PTT and a PTT ratio calculated for the day(s) they deteriorated or bled. The percentage of all PTTs obtained for each patient that were <1.5xcontrol or >3.0xcon-trol were calculated.
To determine whether predictors of clinical outcome exist, we examined the percentages of patients with various clinical characteristics and those at various heparin doses and levels of anticoagulation who stabilized, worsened, or hemorrhaged.
Results
During the 68 months of the study, 269 patients with ischemic stroke were treated with heparin. Of these 269 patients, 73 received heparin for treatment of progressive stroke. Four of the 73 were excluded from analysis because of insufficient data. All of the remaining 69 patients had a CT scan <48 hours after hospital admission. None of the initial CT scans demonstrated hemorrhage or mass lesions. Thirtyfour patients (49%) had at least one follow-up CT scan, performed a median of 3 days after the initial scan. In the three patients with a history of progression before hospital admission, heparin treatment was begun <4 hours after admission, immediately after cerebral hemorrhage was ruled out by CT and hypertension, if present, was controlled. Progression occurred after hospitalization in 66 patients, and in these patients heparin treatment was started after obtaining a CT scan. In 18 patients (26%) heparin therapy was not begun until >24 hours after the onset of symptoms.
Nine patients in this series (13%) died in the hospital, from 1 day to 3 months (median 10 days) after admission. Causes of death included vertebralbasilar stroke in four patients, hemorrhage into a cerebral infarction in two, sepsis in two, and upper gastrointestinal tract hemorrhage in one.
Twenty-seven patients (39%) continued to deteriorate while on heparin therapy. None of these patients worsened due to hypotension, cardiac arrhythmia, or herniation, although two deteriorated as a result of intracerebral hemorrhage ( Table 1) ; both of these patients died. Ten of the remaining 25 patients died or developed severe deficits (plegia in one or Analysis of whether stroke location predicted clinical deterioration while on heparin was not done since in approximately one third of the patients the location was indeterminate. Furthermore, stroke location was not consistently predictive of the presence or absence of extracranial carotid artery disease. Of the 48 patients with carotid-distribution strokes, 20 had a subcortical and 11 a cortical infarct; in the remaining 17 patients the infarct location was indeterminate. Thirteen of the 31 patients with a carotiddistribution subcortical or cortical infarct had a carotid ultrasound or cerebral angiogram; a >40% stenosis of the ipsilateral carotid artery was demonstrated in four of eight patients with a subcortical and three of five patients with a cortical infarct.
A cardiac etiology for the stroke could not be established with any certainty in the 13 patients with a cardiac source of emboli, so this variable was also excluded from the analysis of clinical predictors of outcome. Six of these 13 patients had an infarct in a location or distribution unusual for cardioembolic stroke (subcortical or vertebral-basilar), and none of the six had CT evidence of a previous infarct. Moreover, since angiography was not done in most of these 13 patients, information about the cerebral vasculature was not available to aid in diagnosis.
In the analysis of clinical predictors of outcome for patients treated with heparin for progressive ischemic stroke, age, sex, the arterial distribution of the stroke, and the number who began heparin treatment at least 1 day after the onset of symptoms were similar in patients who stabilized or worsened while on heparin (Table 2 ). There was no relation between any of the treatment variables examined (heparin dose, mean PTT, or PTT ratio) and clinical worsening (Table 3) . Furthermore, the percentage of PTTs that were < 1.5 x control did not differ between patients who were stable and those who worsened.
Ten patients (14%) hemorrhaged while on heparin, and all 10 had their heparin subsequently discontinued, either temporarily or permanently. The site of hemorrhage included the brain in three patients, the thigh/groin in three, the gastrointestinal tract in two, the nose in one, and a fractured hip in one. The incidence of clinically silent cerebral hemorrhage may have been underestimated since only 34 patients (49%) had a repeat CT scan. In our series, two of the three patients with brain hemorrhage deteriorated clinically and then died. In the third patient, the hemorrhage was not associated with clinical worsening but was discovered on a repeat CT scan.
The clinical variables age, sex, number of days on heparin, and concurrent use of heparin and antiplatelet therapy were similar in patients who hemorrhaged and those who did not (Table 4) . Twenty percent (two) of the 10 patients who experienced hemorrhagic complications while on heparin and 20% (12) of the 59 who did not were receiving aspirin, either alone or in combination with dipyridamole or sulfinpyrazone, before the onset of their stroke. Of the 62 patients who received a 2,500-10,000 unit bolus of heparin prior to infusion, nine (15%) had a hemorrhagic complication, a rate similar to that in the seven patients not receiving a bolus (one, 14%). Fourteen patients had more than one heparin bolus during their treatment course; none of these 14 patients hemorrhaged. Four patients had invasive procedures (two had digital intravenous angiography, one had cerebral angiography, and the other had a pelvic biopsy) within a day of starting heparin or while on heparin; none of these patients hemorrhaged at the site of their procedure.
None of the treatment variables examined (heparin dose, mean PTT, PTT ratio, or percentage of PTTs > 3.0 x control) correlated with hemorrhagic complications (Table 5) . 
Discussion
Duke et al 9 reported that approximately 20% of ischemic stroke patients with a partial stable deficit experience subsequent clinical worsening whether treated with heparin or not. In a different population of stroke patients (those with progressive deficits), we found that 36% continued to deteriorate while receiving heparin and an additional 3% worsened due to intracerebral hemorrhage. Few other studies have reported on the short-term outcome of patients with progressive stroke. In 1958, Fisher 5 reported on 14 patients with progressive stroke treated with heparin and 14 unmatched, untreated controls; three of the treated patients and nine of the untreated patients progressed to severe deficits. In a preliminary report of a later cooperative study examining the effects of heparin on patients with progressive stroke, Fisher 6 found six instances of worsening that occurred within 2 weeks in the treated group of 51 patients compared with 11 instances in the untreated group of 49 patients. In both of these studies patients were treated with intermittent intravenous heparin and oral dicumarol; heparin was discontinued after a therapeutic prothrombin time was obtained. Haley et al 8 reported that 18 of 36 consecutive patients with progressive stroke treated with heparin experienced neurologic worsening despite treatment. In that study the incidence of further progression was greater in patients with carotid-distribution infarcts than in those with vertebral-basilar-territory infarcts, a distinction we did not confirm.
The issue of whether continued progression in patients treated with heparin was due to inadequate anticoagulation is important in evaluating heparin's effectiveness for progressive stroke. Fisher 5 found that in all three of the 14 patients treated with heparin who deteriorated, either the onset of anticoagulation was delayed or inadequate doses of heparin were given. The level of anticoagulation in the six treated patients who worsened in the cooperative study was not given. 6 Haley et al 8 reported that the PTT was > 1.5 x control in all patients who experienced neurologic worsening while on heparin. Whether a threshold effect existed at a higher PTT, however, could not be evaluated from that data. The clinical deterioration in our series was clearly not associated with inadequate anticoagulation. Furthermore, a threshold effect was not seen. Patients receiving large doses of heparin and having high PTTs and PTT ratios were just as likely to progress as patients receiving lower doses and having lower values. This finding is in contrast to the experimental and clinical experience with heparin in patients with venous thromboembolic disease, in whom intravenous heparin adjusted to maintain the PTT at 1.5-2.5 x control prevents thrombus progression and embolism. 10 - 13 We were unable to relate hemorrhagic complications to age, sex, number of days on heparin, antiplatelet therapy prior to stroke onset, concurrent heparin and antiplatelet therapy, or invasive procedures. Most studies investigating heparin treatment for venous thrombosis have found no association between age, sex, or duration of heparin treatment and hemorrhagic complications. 13 
"
18 The data about whether antiplatelet agents or vascular damage increase the risk of hemorrhage in heparin-treated patients is conflicting. The primary purpose of our study was to determine the acute outcome of patients treated with heparin for progressive stroke. Ours is the largest series of such patients reported to date. The percentage of patients with progressive deficits while receiving heparin, reported by others in more limited series, varies from 12% to 50%.
-

6
- 8 This wide range suggests that other factors besides heparin therapy influence outcome and that thrombus extension is not responsible for progressive deficits in all stroke patients, as demonstrated by autopsy and angiographic studies. 2021 We examined clinical characteristics and laboratory variables that might influence outcome and help predict favorable risk/benefit ratios for heparin use. Unfortunately, we did not find any clinical predictors of worsening or hemorrhage. Furthermore, we showed that neither continued progression nor hemorrhagic complications were related to heparin dose, mean PTT, or PTT ratio.
The large percentage of patients who continued to worsen while on heparin and the lack of a dose response for heparin in preventing this deterioration may raise doubts concerning heparin's effectiveness for progressive stroke. Our results, however, should not be interpreted as either supporting or refuting the use of heparin for progressive stroke. Given the limited therapeutic options at this time, most clinicians managing such patients will continue to use heparin until reliable evidence is available demonstrating its ineffectiveness. Our results suggest that this decision should not be governed by such clinical factors as a patient's age or sex or by the vascular distribution of the stroke. Furthermore, since the PTT does not correlate with outcome, frequent measurements and overzealous efforts to adjust it may be unnecessary. Our results also support the use of limited exclusion criteria based on clinical features and broad acceptable PTT ranges in future controlled trials designed to examine heparin's efficacy for progressive stroke.
